Entero Therapeutics Net Income

Entero Therapeutics (ENTO) currently reports a net income of $-8.7M as of March 2026. That compares with $-25M in the prior-year period — up 64.9% year over year. That is below the sector sector average of $100M. Use the charts on this page to explore Entero Therapeutics's net income history and peer comparisons.

Entero Therapeutics's net income increased from $-25M to $-8.7M — a 64.9% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Entero Therapeutics's net income of $-8.7M is lower than the its sector sector average of $100M. That is roughly 108.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Entero Therapeutics reported $-8.7M in net income as of March 2026. That compares with $-25M in the prior-year period — up 64.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-8.7M, then check the historical chart for trend and the peer comparison chart for relative positioning. The sector average is $100M. From there, open related valuation or income-statement pages for Entero Therapeutics, and consider following ENTO for alerts when major investors trade the stock.